Research Studies

Sign up by: December 31, 2026

This is a multisite study which aims to evaluate and characterize genetic frontotemporal dementia (FTD) patients and asymptomatic individuals belonging to family with a strong history of an FTD. Researchers seek to better understand the brain changes that occur in FTD and which measures are best for tracking change and predicting progression. Various measures including brain imaging, eye tracking, blood markers and neuropsychological testing will be measured.

For more information, check out their website at GENFI – The Genetic Frontotemporal Initiative.

Key Details

Study Sponsor: Canadian Institutes for Health Research (CIHR)

Location: In-person (2075 Bayview Ave, Toronto ON M4N 3M5)

How Often: Yearly

Compensation: Meal voucher and parking passes provided at each visit.

Contact: Sabrina Armstrong, Clinical Research Coordinator

[email protected]

416-480-6100 ext. 1620

Sign up by: 31 December 2025

Nabilone is a drug that has been shown in previous studies to improve the symptoms of patients with moderate to severe Alzheimer's Disease (AD) including agitation in small studies, as well as cognition and caregiver distress, with minimal side effects - a stark contrast to existing and prospective treatments showing various drawbacks. The overall objective of this study is to assess the safety and efficacy of nabilone for managing agitation in patients with AD in large multi-center study and to identify biological markers for assessing agitation severity and treatment response. This study will also review whether Nabilone is beneficial for other outcomes, such as overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, pain, and global function in patients with moderate-to-severe AD over 9 weeks.

Key Details

Study Sponsor: The regulatory sponsor for this study is Sunnybrook Research Institute (SRI), with their Centre for Clinical Trial Support (CCTS) being the coordinating centre for the study. The funding agencies supporting this study are the Alzheimer's Drug Discovery Foundation (ADDF), and the Weston Brain Institute (WBI).

Location: In-person (700 Gordon Street, Whitby, ON) and phone

How Often: intake of drug required daily

Compensation: You may be reimbursed for parking or transportation to the clinic.

Contact

Dr. Amer Burhan, Geriatric Psychiatrist

[email protected]

905-430-4055 Ext 6053

Sign up by: 01 February 2026

This study is testing a new AI-powered digital reminder app that helps people with dementia with daily tasks. It also sends alerts to the caregiver if there are changes in routine, like missing a reminder or doing things at a different time. People living with dementia and their caregivers will use the app at home for 4 to 8 weeks. The app will show alerts and ask caregivers for feedback. This helps improve how the app works. At the end of the study, people living with dementia and their caregivers will be asked what they liked or didn't like and how the app could be better. The goal is to make a tool that helps people stay independent and supports caregivers in daily care.

Key Details
Study Sponsor: AGE-WELL NCE and the Canadian Institutes of Health Research
Location: Participant's home in the Greater Toronto Area (GTA)
How Often: 2-5x weekly
Compensation: $30 upon completion of the 4-8 week usability testing

Contact: Joy Lai, MASc Student
[email protected]
613-985-1447